VANCOUVER, Aug. 17 /PRNewswire/ - iCo Therapeutics Inc. announced today
the appointment of Dr. Peter Hnik as Chief Medical Officer. Dr. Hnik is an
ophthalmologist with a focus in glaucoma, neuro-ophthalmology, and deep
industrial experience in retinal diseases such as age related macular
degeneration and diabetic retinopathy.
"Dr. Hnik's clinical background represents an enormous asset to our
management team and its maturation," said Andrew Rae, iCo Therapeutics'
President and Chief Executive Officer. "His expertise in not only
ophthalmology but also in other medical fields strengthens our position as
we continue to build our pipeline and develop clinical stage drugs for a
range of new conditions affecting isolated biological environments."
Prior to joining iCo Therapeutics, Dr. Hnik served as Associate
Director of Clinical Research with QLT Inc., playing a critical role in
designing and directing Visudyne clinical trials in AMD and diabetic
retinopathy. Dr. Hnik was also heavily involved in the publication,
in-licensing and pharmacovigilance activities for Visudyne.
"iCo Therapeutics is a company with an innovative business model, a
talented management team and experienced, active advisory boards. With
these fundamental building blocks in place, I am very enthusiastic about
the prospects for the Company and my role in the company's evolution", said
Dr. Hnik received his medical degree from the Medical Faculty of
Charles University of Prague in 1981. After practicing for years at the Eye
Clinic of the Charles University Hospital where he performed surgery and
consultation in glaucoma and neuro-ophthalmology, Dr. Hnik later joined the
Eye Clinic of the University of British Columbia as part of the glaucoma
research group. He received his Master of Health Sciences degree from the
University of British Columbia in 1999. He is a member of the Association
for Research in Vision and Ophthalmology (ARVO), the American Academy of
Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA)
and the Drug Information Association (DIA).
iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
company focused on developing pre-existing drugs for a range of new
conditions affecting isolated biological environments - areas such as the
eye, spinal cord, or joints - where locally-administered application of
these therapies would have minimal systemic distribution and fewer safety
For more information, visit the company website at:
CONTACT: Business Development Contact: Dr. John Clement, CT&DO, (778)
688-0644; Finance/Investor Contact: Mr. John Meekison, CFO, (604) 602-9414;
Media Contact: Amanda Smith, Principal, Smith Biotech, (778) 846-4116
SOURCE iCo Therapeutics Inc.